HIV-ASSOCIATED CO-MORBIDITIES: Edited by Morris Schambelan and Todd T. BrownCommunicable and noncommunicable liver disease in HIVMauss, Stefana; Boesecke, ChristophbAuthor Information aCenter for HIV and Hepatogastroenterology, Duesseldorf bDepartment of Medicine I, University Hospital Bonn, Bonn, Germany Correspondence to Dr Stefan Mauss, Center for HIV and Hepatogastroenterology, Humboldt Strasse 18, Duesseldorf 40237, Germany. Tel: +49 211 239 552 21; fax: +49 211 239 552 60; e-mail: [email protected] Current Opinion in HIV and AIDS: May 2021 - Volume 16 - Issue 3 - p 152-155 doi: 10.1097/COH.0000000000000675 Buy Metrics Abstract Purpose of review The aim of this study was to highlight the profound changes in the cause in chronic liver disease in HIV-infected individuals. Recent findings Hepatitis C virus (HCV) has been transformed into a curable viral infection by highly effective treatments. This has resulted in elimination of chronic hepatitis C in HIV-coinfected individuals at least in resource-rich settings. Hepatitis B virus (HBV) has become a chronic infection, which is easily controlled by long-term therapy with HBV polymerase inhibitors. As a result, nonalcoholic steatohepatitis (NASH) has gained clinical importance. The obesity epidemic in the general population has also included people with HIV and weight gain has been associated with some newer antiretroviral drugs, such as HIV integrase inhibitors and tenofovir alafenamide fumarate. Medical treatment for obesity is a focus of intense research efforts, but currently, the only convincing therapeutic option in morbidly obese patients is bariatric surgery, which can also improve liver outcomes. The wider use of this approach has included HIV-infected individuals allowing to assess at least the safety aspects of bariatric surgery in this special population. Summary The shift from communicable to noncommunicable liver disease is changing the clinical practice in HIV-infected individuals. Research activities are focusing more on treatment of NASH and obesity, although a curative therapy for HBV infection would have a great clinical impact. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.